PPT-ARVs

do not get rid of HIV from the body they stop the production of virus HIV IS A VIRUS HIV virus HIV virus DEFENCE CELL DEFENCE CELLS PROTECT US FROM DISEASES HIV virus DEFENCE CELL. Fostemsavir. , . prodrug. of . temsavir. . (. attachment . inhibitor. ). AI438011 . Study. TAF (TFV . prodrug. ). Study . 292-0102. Study . 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. TRIPS Flexibilities and . Access to Medicines in . Lesotho – . a public health view. Presentation to Civil Society meeting. Maseru. 12 August 2014. No access to medicines?. Local (clinic) – ordering, staff, calculations, overuse. Module 11:. Family Planning and PMTCT Services for Adolescents. 1. Module 11 Learning Objectives. After completing this module, participants will be able to:. . List the risks of adolescent pregnancy. Marion County Public Health Department. Northwest District Health Office. Chapters. Chapter 1: One Day on NOD…. Chapter 2: The Initial Visit. Chapter 3: The Hospital Admission. Chapter 4: The HIV Diagnosis. the Centers. for Disease Control and Prevention (CDC) under the terms of cooperative agreement #U2GGH000994. Its contents are solely the responsibility of the authors and do not necessarily represent the views of the U.S. Government.. Learning Objectives. Understand key counseling techniques. Learn and apply motivational interviewing tools to adherence counseling. Outline. Key Counseling Techniques . Therapeutic Alliance. Collaborative Health Education. . in . Middle-Income Countries. Othoman. Mellouk. ITPC-MENA. 1st vague of . generic. . competition. . is. . unlikely. to . happen. …. Significant. . increase. in . access. to . treatment. : 14M. functioning. Luis . Sagaon. . Teyssier. ; Yves Arrighi; . Boniface Dongmo Nguimfack; Jean-Paul Moatti. Aknowledgements. This study is part of a project funded by . UNITAID. and developed by:. The French National Agency for Research on AIDS and viral Hepatitis . What the Primary Care Provider Should Know. Carolyn K. Burr, . EdD. , RN. Co-Clinical Director NY/NJ AETC LPS. Deputy Director . François-Xavier Bagnoud Center. December 17. th. , 2013. Support for this program is provided in part through an educational training grant from the New Jersey Department of Health (NJDOH), Division of HIV,STD and TB Services.. Basic principles of DDIs with ARVs: an introduction David Back University of Liverpool DDIs : Are not going away! Ageing Population Polypharmacy Increased use of ‘Over the Counter ’ Online access to drugs , . prodrug. of . temsavir. . (. attachment inhibitor). AI438011 Study. TAF (TFV . prodrug. ). Study 292-0102. Study 299-0102. Doravirine (non nucleoside reverse transcriptase inhibitor). MK1439007 Study. 1 J i v i n g w i t h S c i e n c e C D 1 E n g l i s h S c r i p t Knock knock MaThemba : Yes, who is that? Thandi : Hello Ma, it is me Thandi from the Africa Centre (AC). MaThemba : Yes, How can Adherence. Counseling. Flipchart. Adults, non-pregnant. nor breastfeeding. The mark “CDC” is owned by the US Dept. of Health and Human Services and is used with permission. Use of this logo is not an endorsement by HHS or CDC of any particular product, service, or enterprise..